 |
| |
| Feb-20-19 | Resumed |
Citigroup |
Neutral |
$41 |
|
| Jan-31-19 | Upgrade |
Credit Suisse |
Neutral → Outperform |
|
|
| Jan-31-19 | Upgrade |
Argus |
Hold → Buy |
|
|
| Jan-23-19 | Downgrade |
UBS |
Buy → Neutral |
|
|
| Dec-11-18 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Nov-01-18 | Downgrade |
BMO Capital Markets |
Outperform → Market Perform |
|
|
| Jun-08-18 | Initiated |
Cantor Fitzgerald |
Overweight |
$45 |
|
| Apr-05-18 | Downgrade |
Barclays |
Overweight → Equal Weight |
$41 → $38 |
|
| Jan-29-18 | Reiterated |
SunTrust |
Hold |
$33 → $40 |
|
| Sep-20-17 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Jul-20-17 | Downgrade |
Credit Suisse |
Outperform → Neutral |
|
|
| May-16-17 | Downgrade |
Citigroup |
Neutral → Sell |
|
|
| Dec-02-16 | Initiated |
Guggenheim |
Neutral |
|
|
| Nov-02-16 | Downgrade |
Argus |
Buy → Hold |
|
|
| Oct-13-16 | Downgrade |
Jefferies |
Buy → Hold |
|
|
| Jun-20-16 | Reiterated |
Jefferies |
Buy |
$42 → $40 |
|
| May-12-16 | Initiated |
Berenberg |
Hold |
$38 |
|
| May-04-16 | Reiterated |
UBS |
Buy |
$36 → $38 |
|
| Apr-18-16 | Resumed |
Goldman |
Neutral |
$35 |
|
| Apr-07-16 | Resumed |
Morgan Stanley |
Equal-Weight |
$35 |
|
|
|
| Mar-25-19 10:53AM | S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion PR Newswire |
| Mar-22-19 01:24PM | Final Trades: Verizon, XPO, Pfizer, Alphabet and BB&T CNBC Videos |
| 11:23AM | Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan Zacks |
| 08:02AM | Dow 30 Stock Roundup: AAPL Refreshes Product Lineup, BA Wins $327M Navy Order Zacks |
| Mar-21-19 01:00PM | Boeing's Lesson About The Dow ETF.com |
| 10:10AM | Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market Zacks |
| 09:51AM | Pfizer buys stake in French gene company in deal worth up to $636M American City Business Journals |
| Mar-20-19 03:17PM | Invest in Americas Rising Healthcare Costs With These Stocks InvestorPlace |
| 01:37PM | Pfizer buys stake in French gene therapy firm Vivet Reuters |
| 11:30AM | Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study Zacks |
| 11:10AM | Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan Zacks |
| 10:43AM | Glaxo Presents Encouraging Data on Endometrial Cancer Drug Zacks |
| 09:33AM | Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million TheStreet.com |
| 07:54AM | Pfizer Adds to Big Pharma's Gene-Therapy Deal Streak The Wall Street Journal |
| 07:46AM | The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company Benzinga |
| 07:20AM | Pfizer acquires option to buy Vivet Therapeutics for equivalent of $635.8 million MarketWatch |
| 06:45AM | Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics Business Wire |
| 06:00AM | 5 High-Quality, High-Yielding Stocks Morningstar |
| 04:16AM | Stocks - FedEx, Google Fall in Pre-market; General Mills Jumps Investing.com |
| Mar-19-19 07:15PM | Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer PR Newswire |
| 05:45PM | Pfizer (PFE) Gains As Market Dips: What You Should Know Zacks |
| 12:28PM | Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105 Zacks |
| 11:51AM | Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients Zacks |
| 10:31AM | 3 Stocks to Build Your Portfolio Around Motley Fool |
| 10:21AM | Why You Should Buy ABBV Stock for Income and Value InvestorPlace |
| 10:00AM | Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts Business Wire |
| Mar-18-19 06:44PM | Bristol-Myers & Pfizer Release Phase IV Data on Eliquis Zacks |
| 01:36PM | Big Pharma Earnings Might Not Be as Good as They Look Barrons.com |
| 11:17AM | UnitedHealth Shares Finding Their Mojo Again Investing.com |
| 09:54AM | Group with consumer-friendly vibe pushes drugmakers' message Associated Press |
| 09:01AM | The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J Zacks |
| Mar-17-19 11:45AM | AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention Business Wire |
| Mar-15-19 10:58AM | Pisani: S&P rebalancing as some companies aggressively buy back stock CNBC Videos |
| 10:31AM | Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others Zacks |
| 10:09AM | Dow 30 Stock Roundup: PFE's Herceptin Biosimilar Gets FDA Nod, VZ to Launch 5G Soon Zacks |
| 08:00AM | The Case Against Pfizer Stock and the Rest of the Industry InvestorPlace |
| Mar-14-19 04:12PM | Markets Right Now: Stocks end a wobbly day mostly lower Associated Press |
| 01:36PM | What's the play on Wynn? Plus the trades on Citigroup & Pfizer in #AskHalftime CNBC Videos |
| 05:01AM | Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades Investopedia |
| Mar-13-19 05:45PM | Pfizer (PFE) Gains But Lags Market: What You Should Know Zacks |
| 02:27PM | Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study Zacks |
| 01:10PM | Lilly's Cyramza Successful in Phase III First-Line NSCLC Study Zacks |
| 12:50PM | Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma Zacks |
| 08:37AM | FDA medical adviser: 'Congress is owned by pharma' Yahoo Finance |
| Mar-12-19 04:28PM | BioNTech hires banks for IPO worth up to $800 million -sources Reuters |
| 02:06PM | BioNtech hires banks for IPO worth up to $800 million - sources Reuters |
| 01:29PM | Biontech stock offering could be worth as much as $800 million-sources Reuters |
| 01:20PM | Option trading opportunities in Pfizer & Sirius XM CNBC Videos |
| 10:50AM | Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval Zacks |
| 10:01AM | Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation Zacks |
| Mar-11-19 07:37PM | U.S. FDA Approves Pfizers Oncology Biosimilar TRAZIMERA (trastuzumab-qyyp), a Biosimilar to Herceptin®1 Business Wire |
| 07:25PM | Stocks Spike on M&A and Retail Sales Investopedia |
| 04:56PM | FDA approves Pfizer's biosimilar to Roche's Herceptin Reuters |
| 04:39PM | FDA approves Pfizer's biosimilar to Roche's Herceptin Reuters |
| 10:57AM | Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus Zacks |
| 10:06AM | The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's Zacks |
| Mar-08-19 01:45PM | Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs Zacks |
| 01:00PM | Exchange Traded Funds: How To Find The Best ETFs Investor's Business Daily |
| Mar-07-19 02:47PM | 5 Top Gene-Editing Stocks for 2019 Motley Fool |
| Mar-06-19 01:19PM | The Roche Merger Will Do Wonders for Spark Stock InvestorPlace |
| 12:56PM | GlycoMimetics Inc (GLYC) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 11:34AM | Lilly's Emgality Gets FDA Priority Review for Cluster Headache Zacks |
| 11:25AM | Demographics are favorable for the healthcare sector Yahoo Finance Video |
| Mar-05-19 12:21PM | 10 Hot Stocks to Buy Right Now InvestorPlace |
| 10:05AM | AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes PR Newswire |
| 10:00AM | Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference Business Wire |
| 09:00AM | Lilly to Bring Half-Priced Version of Popular Humalog Insulin Zacks |
| 07:24AM | The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings Benzinga |
| 06:47AM | [$$] Scott Gottlieb to step down as head of FDA Financial Times |
| Mar-04-19 08:57PM | Pfizer Prices $5,000,000,000 Debt Offering Business Wire |
| 04:24PM | This Biotech Stock Just Flew To A Record After Topping Pfizer In A Study Investor's Business Daily |
| 12:31PM | Here's Why Ascendis Pharma Is Rocketing Higher Today Motley Fool |
| 11:25AM | Pfizer Inc. -- Moody's assigns A1 rating to Pfizer's notes; stable outlook Moody's |
| 10:05AM | AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab Zacks |
| 09:19AM | Can This Biotech Puppy Run With the Big Dogs? Motley Fool |
| 08:20AM | Market Trends Toward New Normal in Pfizer, Hyatt Hotels, Wipro, Garmin, Ameren, and Qorvo Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire |
| 08:00AM | BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer GlobeNewswire |
| Mar-01-19 09:29AM | Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices Zacks |
| 09:26AM | Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended Zacks |
| 09:00AM | Nektar Therapeutics (NKTR) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 08:35AM | Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer Business Wire |
| Feb-28-19 10:01PM | Pfizer unit Meridian under civil investigation by U.S. Attorney Reuters |
| 09:40PM | ICU Medical Inc (ICUI) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 06:02PM | Top technician says charts point to healthy gains ahead for this stock CNBC Videos |
| 03:53PM | 5 Pharmaceutical Stocks With Big Moats and Bridges Kiplinger |
| 12:31PM | Antares Pharma Inc (ATRS) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 08:00AM | Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older Business Wire |
| Feb-27-19 03:49PM | Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You Motley Fool |
| 11:20AM | The patent system keeps American drug prices so high Yahoo Finance Video |
| Feb-26-19 06:16PM | Lawmakers grill top pharma execs over high drug costs CNBC Videos |
| 05:37PM | Senators grill pharmaceutical executives over rising drug prices Yahoo Finance Video |
| 04:21PM | Fed Chair Jerome Powell slams ballooning healthcare spending Yahoo Finance Video |
| 03:19PM | Congress Grills Drugmakers: 5 Key Takeaways Motley Fool |
| 02:40PM | Corcept (CORT) Q4 Earnings Beat Estimates, Revenues In Line Zacks |
| 01:42PM | The Latest: Senators urge pharma CEOs to rein in lobbyists Associated Press |
| 12:07PM | Senators say will support Judiciary panel if it looks into drug patents Reuters |
| 10:49AM | Senators grill pharma execs over prescription drug prices Yahoo Finance |
| 10:34AM | Aerie (AERI) Q4 Earnings Miss, Rhopressa Gains Traction Zacks |
| Feb-25-19 07:50PM | [$$] Pharmaceutical Industry CEOs Face Senate Hearing on Drug Prices The Wall Street Journal |
| 05:54PM | Technician says it's time to fade the biotech rally CNBC Videos |
|
|
|
|
| Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names. Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Merck KGaA; licensing agreement with BionTech AG; collaboration agreements with Merck & Co., Inc. and Eli Lilly & Company. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| JOHNSON RADY A | Executive Vice President | Mar 15 | Sale | 41.13 | 8,700 | 357,831 | 59,797 | Mar 18 06:37 PM | | READ IAN C | Executive Chairman | Mar 04 | Sale | 43.29 | 50,788 | 2,198,474 | 1,639,280 | Mar 06 04:03 PM | | READ IAN C | Executive Chairman | Mar 04 | Sale | 43.17 | 530,078 | 22,882,702 | 1,109,202 | Mar 06 04:03 PM | | SUSMAN SALLY | Executive Vice President | Mar 04 | Sale | 43.26 | 8,725 | 377,444 | 172,094 | Mar 06 03:29 PM | | SUSMAN SALLY | Executive Vice President | Mar 04 | Sale | 43.14 | 63,998 | 2,760,698 | 108,096 | Mar 06 03:29 PM | | Dolsten Mikael | President R&D | Mar 04 | Sale | 43.52 | 49,082 | 2,136,293 | 289,126 | Mar 05 04:54 PM | | ROGERS DAWN | Executive Vice President | Mar 04 | Sale | 42.98 | 15,002 | 644,798 | 14,920 | Mar 05 04:55 PM | | Dolsten Mikael | President R&D | Mar 01 | Option Exercise | 31.34 | 106,191 | 3,328,057 | 438,679 | Mar 05 04:54 PM | | Dolsten Mikael | President R&D | Mar 01 | Sale | 43.56 | 100,471 | 4,376,852 | 338,208 | Mar 05 04:54 PM | | ROGERS DAWN | Executive Vice President | Feb 27 | Option Exercise | 32.23 | 19,297 | 621,942 | 45,049 | Mar 01 07:47 PM | | SUSMAN SALLY | Executive Vice President | Feb 27 | Option Exercise | 32.23 | 85,763 | 2,764,141 | 228,743 | Mar 01 07:47 PM | | YOUNG JOHN D | Group President | Feb 27 | Option Exercise | 32.23 | 154,374 | 4,975,474 | 441,923 | Mar 01 07:47 PM | | GOETTLER MICHAEL | Group President | Feb 27 | Option Exercise | 32.23 | 30,017 | 967,448 | 48,652 | Mar 01 07:37 PM | | Hwang Angela | Group President | Feb 27 | Option Exercise | 32.23 | 11,792 | 380,056 | 23,635 | Mar 01 07:37 PM | | JOHNSON RADY A | Executive Vice President | Feb 27 | Option Exercise | 32.23 | 30,017 | 967,448 | 81,341 | Mar 01 07:37 PM | | LANKLER DOUGLAS M | Executive Vice President | Feb 27 | Option Exercise | 32.23 | 64,322 | 2,073,098 | 123,145 | Mar 01 07:37 PM | | Lewis-Hall Freda C | Executive Vice President | Feb 27 | Option Exercise | 32.23 | 81,475 | 2,625,939 | 416,278 | Mar 01 07:37 PM | | BOURLA ALBERT | Chief Executive Officer | Feb 27 | Option Exercise | 32.23 | 64,322 | 2,073,098 | 331,982 | Mar 01 07:29 PM | | CANGIALOSI LORETTA V | Sr. Vice President, Controller | Feb 27 | Option Exercise | 32.23 | 25,729 | 829,246 | 121,743 | Mar 01 07:29 PM | | DAMELIO FRANK A | Executive Vice President | Feb 27 | Option Exercise | 32.23 | 182,247 | 5,873,821 | 588,177 | Mar 01 07:29 PM | | YOUNG JOHN D | Group President | Feb 23 | Option Exercise | 21.03 | 43,724 | 919,516 | 312,403 | Feb 26 07:45 PM | | JOHNSON RADY A | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 18,004 | 378,624 | 61,182 | Feb 26 07:45 PM | | BOURLA ALBERT | Chief Executive Officer | Feb 23 | Option Exercise | 21.03 | 36,008 | 757,248 | 191,438 | Feb 26 07:45 PM | | Lewis-Hall Freda C | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 87,449 | 1,839,052 | 388,024 | Feb 26 07:45 PM | | DAMELIO FRANK A | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 185,185 | 3,894,441 | 522,576 | Feb 26 07:45 PM | | SUSMAN SALLY | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 97,737 | 2,055,409 | 205,833 | Feb 26 07:46 PM | | LANKLER DOUGLAS M | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 43,724 | 919,516 | 83,781 | Feb 26 07:45 PM | | MACKENZIE ALEXANDER R | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 41,615 | 875,163 | 144,164 | Feb 26 07:10 PM | | CANGIALOSI LORETTA V | Sr. Vice President, Controller | Feb 23 | Option Exercise | 21.03 | 30,864 | 649,070 | 115,139 | Feb 26 07:10 PM | | ROGERS DAWN | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 19,290 | 405,669 | 37,638 | Feb 26 07:10 PM | | GOETTLER MICHAEL | Group President | Feb 23 | Option Exercise | 21.03 | 19,290 | 405,669 | 31,507 | Feb 26 07:11 PM | | LANKLER DOUGLAS M | Executive Vice President | Feb 01 | Sale | 42.75 | 5,000 | 213,750 | 40,057 | Feb 01 07:21 PM | | Dolsten Mikael | President R&D | Jan 31 | Option Exercise | 29.78 | 125,968 | 3,751,425 | 362,051 | Feb 01 07:28 PM | | LANKLER DOUGLAS M | Executive Vice President | Jan 30 | Sale | 41.19 | 38,800 | 1,598,071 | 45,057 | Feb 01 07:21 PM | | READ IAN C | Chairman & CEO | Nov 02 | Option Exercise | 26.64 | 1,100,201 | 29,312,588 | 1,760,958 | Nov 06 03:46 PM | | PFIZER INC | 10% Owner | Oct 15 | Buy | 18.00 | 55,556 | 1,000,008 | 22,032,040 | Oct 17 05:17 PM | | Dolsten Mikael | President R&D | Sep 13 | Option Exercise | 24.56 | 181,712 | 4,462,167 | 234,299 | Sep 17 04:08 PM | | OLSON LAURIE J | Executive Vice President | Aug 13 | Sale | 41.00 | 10,214 | 418,774 | 72,672 | Aug 14 05:04 PM | | MACKENZIE ALEXANDER R | Executive Vice President | Aug 03 | Sale | 39.51 | 25,642 | 1,013,171 | 102,412 | Aug 06 03:19 PM | | GOETTLER MICHAEL | Group President | Aug 01 | Sale | 39.70 | 19,198 | 762,116 | 11,924 | Aug 03 03:38 PM | | CANGIALOSI LORETTA V | Sr. Vice President, Controller | Aug 01 | Sale | 40.16 | 26,814 | 1,076,933 | 83,846 | Aug 03 03:36 PM | | LUND-JURGENSEN KIRSTEN | Executive Vice President | Aug 01 | Sale | 40.04 | 20,942 | 838,572 | 4,643 | Aug 03 03:35 PM | | DAMELIO FRANK A | Executive Vice President | Aug 01 | Sale | 40.00 | 150,484 | 6,019,360 | 337,391 | Aug 03 03:33 PM | | SUSMAN SALLY | Executive Vice President | Jul 20 | Sale | 37.22 | 40,381 | 1,502,925 | 115,096 | Jul 24 01:09 PM | | READ IAN C | Chairman & CEO | Jul 16 | Sale | 37.36 | 486,753 | 18,186,315 | 659,440 | Jul 17 04:59 PM | | OLSON LAURIE J | Executive Vice President | Jun 06 | Sale | 36.45 | 19,000 | 692,582 | 82,886 | Jun 08 01:11 PM | | CORNWELL W DON | Director | Jun 04 | Sale | 36.40 | 5,223 | 190,117 | 0 | Jun 05 04:44 PM | | READ IAN C | Chairman & CEO | May 01 | Sale | 36.01 | 132,312 | 4,764,081 | 1,144,703 | May 03 04:19 PM |
|
|
|
|
|
|
